Table 3.
Mouse models of ZIKV infection.
| Model | Strain | Deficiency | ZIKV Inoculation | Pathogenesis | Reference |
|---|---|---|---|---|---|
| Immunocompetent | Balb/c | ZIKV2015 (Brazil, 2015) | ZIKV replication | [179] | |
| PRVABC59 (Puerto Rico, 2015) | Viremia | ||||
| Lethality: No | |||||
| SJL | Immunological defects | ZIKV2015 (Brazil, 2015) | ZIKV replication | [179] | |
| Viremia | |||||
| Lethality: No | |||||
| ZIKVBR (Brazil, 2015) | Whole-body growth delay or intra-uterine growth restriction (IUGR) in pups | [144] | |||
| Neonatal | C57BL/6 | PRVABC59 (Puerto Rico, 2015) | Neurological symptoms | [180] | |
| C57BL/6 | MR766 (Uganda, 1947) | Neurological symptoms | [183] | ||
| Kunming | PRVABC59 (Puerto Rico, 2015) | Lethality: Yes (age and dose-dependent) | |||
| ICR | SZ-WIV01 (China, 2016) | ||||
| Balb/c | Z16006 (China, 2016) | Neurological symptoms | [181] | ||
| C57BL/6 | Lethality: Yes/No (mouse strain-specific differences) | ||||
| Kunming | |||||
| Balb/c | MRS_OPY_Martinique_PaRi_2015 | Neurological symptoms | [182] | ||
| (Martinique, 2015) | Lethality: Yes (viral strain-specific differences) | ||||
| GZ01 (Venezuela, 2016) | |||||
| SZ01 (Samoa, 2016) | |||||
| FSS13025 (Cambodia, 2010) | |||||
| C57Bl/6 | Dakar 41519 (Senegal, 1984) | Lethality: Yes (partly) | [176] | ||
| Partially immunocompetent | hSTAT2 KI Mice | hSTAT2 under control mStat2 promotor | Mouse adapted ZIKV-Dak-41525 (=ZIKV-Dak-MA) (Senegal, 1984) | Placental transmission | [196] |
| (C57BL/6) | Lethality: Yes (partially) | ||||
| Genetically Immunocompromised | A192 (129sV) | Ifnar1−/− | MP1751 (Uganda, 1962) | Sever disease | [187] |
| Lethality: Yes | |||||
| FSS13025 (Cambodia, 2010) | Signs of illness | [175] | |||
| Severe disease (age dependent) | |||||
| Lethality: Yes (age dependent) | |||||
| IFNAR−/− | Ifnar−/− | MR 766 (Uganda, 1947) | Severe disease | [176] | |
| (C57BL/6) | Dakar 41519, 41667, 4167 (Senegal, 1984) | Neurological symptoms | |||
| H/PF/2013 (FP, 2013) | Lethality: Yes (age dependent) | ||||
| PRVABC59 (Puerto Rico, 2015) | Severe disease | [180] | |||
| Lethality: Yes | |||||
| FSS13025 (Cambodia, 2010) | Severe disease | [188] | |||
| Lethality: Yes | |||||
| MR 766 (Uganda, 1947 | Severe disease | [70] | |||
| DAKAR 41519 (Senegal, 1984) | Neurological symptoms | ||||
| P6-740 (Malaysia, 1966) | Lethality: Yes | ||||
| FSS13025 (Cambodia, 2010) | (virus strain-specific differences in morbidity and lethality) | ||||
| PRVABC59 (Puerto Rico, 2015) | |||||
| Irf3−/−, Irf5−/−, Irf7−/− TKO | Irf3−/−, Irf5−/−, Irf7−/− | MR 766 (Uganda, 1947), | Severe Disease | [176] | |
| (C57BL/6) | H/PF/2013 (French Polynesia, 2013) | Neurological symptoms | |||
| Lethality: Yes | |||||
| FSS13025 (Cambodia, 2010) | Signs of disease | [189] | |||
| Neurological symptoms | |||||
| Irf3−/−, Irf7−/− DKO | Irf3−/−, Irf7−/− | MR766 (Uganda, 1947) | Viremia | [190] | |
| (C57BL/6) | Lethality: Infrequent | ||||
| AG129 (129/Sv) | Ifnar−/−, Ifngr1−/− | FSS13025 (Cambodia, 2010) | Severe disease | [175] | |
| Neurological symptoms | |||||
| Lethality: Yes | |||||
| H/PF/2013 (French Polynesia, 2013) | Severe disease | [191] | |||
| Lethality: Yes | |||||
| Stat2−/− (C57BL/6) | Stat2−/− | MR 766 (Uganda, 1947) | Severe disease | [70] | |
| DAKAR 41519 (Senegal, 1984) | Neurological symptoms | ||||
| P6-740 (Malaysia, 1966) | Lethality: Yes | ||||
| FSS13025 (Cambodia, 2010) | (virus strain-specific differences in morbidity and lethality) | ||||
| PRVABC59 (Puerto Rico, 2015) | |||||
| Stat1−/− | Stat1−/− | MR 766 (Uganda, 1947) | Viremia | [193] | |
| Disease development | |||||
| Lethality: Yes | |||||
| Chemically immunocompromised | C57Bl/6 | IFNAR1-blocking monoclonal antibody (MAb-5A3 | H/PF/2013 (French Polynesia, 2013) | Viremia/ Increased replication | [176] |
| Lethality: No | |||||
| DAK AR D 41525 (Senegal, 1984) | Viremia | [195] | |||
| Severe disease | |||||
| Lethality: Yes (differences depending on inoculation route) | |||||
| Mouse adapted ZIKV-Dak-41525 (=ZIKV-Dak-MA) (Senegal, 1984) | Viremia | [194] | |||
| Severe Disease | |||||
| Lethality: Yes | |||||
| ZIKV-DAK-41525 (Senegal, 1984) | Lethality: Yes | [196] | |||
| ZIKV-DAK-MA (mouse adapted) | |||||
| C57BL/6 | H/PF/2013 (French Polynesia, 2013) | Viremia in testis and epididymis | [208] | ||
| Mouse adapted ZIKV-Dak-41525 (=ZIKV-Dak-MA) (Senegal, 1984) | |||||
| Balb/c | Dexamethasone | PRVABC59 (Puerto Rico, 2015) | Viral dissemination | [197] | |
| Severe disease (after withdrawal) | |||||
| Lethality: Yes (after withdrawal) |